This represents the first report of differential FXR expression in HCC CSCs, despite previous studies indicating that the selective activation of intestinal FXR can inhibit the abnormal proliferation of Lgr5+ cells and impede colorectal cancer progression. The gene discussed is LGR5; the disease is hepatocellular carcinoma.